Physicians’ Opinions Survey on FDA’s Bydureon Approval

2012-03-06

Physicians were asked to assess their impressions of Bydureon in terms of efficacy, safety, tolerability, expected use, and other important factors. Key questions are broken down by specialty or familiarity to highlight difference in physician perceptions

Highlights

Datamonitor anticipates that the initial enthusiasm will ultimately be muted once physicians gain experience with the drug. Nevertheless, a once-weekly antidiabetic agent clearly represents an attractive option for type 2 diabetes patients, and physicians expect the drug to be a welcome addition to their armamentarium.

FDA’s Bydureon Approval

Published: February 2012
Price
: Single User License US$3800            Corporate User License – US$9500

                    Request Sample


Your key questions answered
  • Assess physicians’ opinions of Bydureon as compared with Amylin’s twice-daily Byetta (exenatide) and Novo Nordisk’s once-daily Victoza (liraglutide)
  • Determine physicians’ expectations for Bydureon’s uptake, line of therapy, and use in combination with other antidiabetics
  • Evaluate how Bydureon may expand the overall market for GLP-1 agonists

Table of Contents

BYDUREON FDA APPROVAL: PHYSICIAN OPINION
Background

SURVEY RESULTS
Demographics
Limited familiarity with PCPs could present a marketing challenge
Impressions of Bydureon’s efficacy differ based on familiarity
Tolerability issues trump safety concerns among physicians familiar with Bydureon
High expectations for Bydureon use will likely come down with increased experience
Endocrinologists expect to use Bydureon in earlier line of therapy compared to PCPs
Combination use with oral antidiabetics is likely
Physicians expect Bydureon to expand the GLP-1 agonist market
Conclusion

APPENDIX
Report methodology
Datamonitor consulting

Disclaimer

List of Figures

Figure: On average, how many patients with type 2 diabetes do you treat per month?
Figure: How familiar are you with Bydureon (once-weekly exenatide)?
Figure: For each attribute below, please select the one drug that you would prefer to prescribe, based on performance (or predicted performance) on that attribute
Figure: Please select the one drug that you would prefer to prescribe, based on efficacy (HbA1c lowering ability)
Figure: Please rank the following potential safety (and tolerability) issues you are most concerned about with Bydureon on a scale of 1 to 7, where 1 is the issue of greatest concern and 7 is the issue of least concern
Figure: Please select the one drug that you would prefer to prescribe, based on injection device
Figure: Where in the treatment algorithm do you think you will most commonly prescribe Bydureon?
Figure: Please consider your hypothetical Bydureon-treated patient population a year post-launch. What percentage of the Bydureon-treated patient population do you expect to have previously been treated with each of the following options?
Figure: Please choose up to three drug classes with which Bydureon could be used in combination. If there are more than three classes, please select the three most likely
Figure: Please give your opinion on how the introduction of Bydureon, and any other market trends, will impact on the number of patients on GLP-1 agonists in the US

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
More Reports
Title Price Buy Now

Global Travel Vaccines Market 2016-2020

As the world continues to move toward globalization, the international travels will keep increasing. This fuels the demand for travel vaccines as the prevalence of infectious diseases are specifically region prone, unlike that of other indications. As vaccines are largely used as a preventive measure against these known infectious diseases, the travelers are advised to follow the region-specific immunization plan. The market is growing because various government bodies have mandated the immunization of travelers visiting the infectious-prone areas with various types of vaccines. This, in turn, prevents the spread of infection and averts any chances of epidemic outbreaks. This analyst forecast the global travel vaccines market to grow at a CAGR of 6.83% during the period 2016-2020. Co......
$2500

Global Lung Cancer Therapeutics Market 2016-2020

Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes almost 85%-90% of the total diagnosed cases. It grows and spreads quite slowly. This analysts forecast the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global lung cancer therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs ......
$2500

Global Alopecia Drugs Market 2016-2020

Alopecia is a loss of hair and can occur at any age across the genders. The exact cause of this disorder is unknown, but many factors are assumed to be responsible for developing alopecia. Few of the primary ones are a sedentary lifestyle, unhealthy diets, and side effects of certain medical treatments. Moreover, hormonal imbalance and aging increase the probability of developing a chronic disease like cancer, arthritis, depression, and hypertension, which would also lead to hair loss, especially among middle-to-late-aged people. This analysts forecast the global alopecia drugs market to grow at a CAGR of 5.02% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global alopecia drugs market for 2016-2020. To ca......
$2500

Global Viscosupplementation Market 2016-2020

Viscosupplementation is a minimally invasive treatment for knee osteoarthritis. It involves the injection of hyaluronic acid into a knee joint to assist the viscous properties of synovial fluid. The procedure increases the joint's functioning and reduces pain. Intra-articular viscosupplementation with hyaluronic acid is gaining acceptance as it is a non-invasive procedure compared to knee replacement. It is categorized into three product segments -- single-injection cycle, three-injection cycle, and five-injection cycle. This analysts forecast the global Viscosupplementation market to grow at a CAGR of 6.23% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global Viscosupplementation market for 2016-2020. To......
$2500

Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020

Immunomodulators are the drugs that help to regulate the immune system. These drugs either stimulate the weak immune systems or moderate the overactive immune systems. Though many drugs are available in the market, there still exists a huge unmet need in the autoimmune and inflammatory immunomodulators market as there are no medicines that provide complete cure to some diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease. This analyst forecast the global autoimmune and inflammatory immunomodulators market to grow at a CAGR of 7.01% during the period 2016-2020. Covered in this report This report covers the present scenario and the growth prospects of the global autoimmune and inflammatory immunomodulators market for 2016-2020. To calculate the market size,......
$2500

Global Pharmaceutical Contract Manufacturing Market 2016-2020

Contract manufacturing involves outsourcing manufacturing products to organizations, which helps the organizations offer the same services at a relatively lower cost. Typically, in the pharmaceutical and biotechnology sectors, the sourcing companies seek contract manufacturing services to restructure their resource deployment toward high skill areas such as R&D and marketing. Contract manufacturing has potential growth opportunities in emerging countries such as India and China. This analyst forecast the global pharmaceutical contract manufacturing market to grow at a CAGR of 6.91% during the period 2016-2020. Covered in this report This report covers the present scenario and the growth prospects of the global pharmaceutical contract manufacturing market for 2016-2020. To calc......
$2500

Global Female Contraceptive Market 2016-2020

Adolescent fertility regulation and pregnancy prevention are important healthcare issues today. Although it is difficult to gauge the full extent of the unmet need for contraception, there is a great need for reproductive and sexual health education owing to the rise in STDs. Research suggests that behavior in adolescence results in a pattern for the rest of an individual's life. The absence of sexual and reproductive healthcare programs for adolescents can result in unwanted pregnancies and unsafe abortions. This analyst forecast the global female contraceptive market to grow at a CAGR of 3.48% during the period 2016-2020. Covered in this report This report covers the present scenario and the growth prospects of the global female contraceptives market for 2016-2020. To calculate ......
$2500

Global Gout Therapeutics Market 2016-2020

Gout is one type of arthritis, which is caused by the high levels of uric acid in the blood. The main symptoms of gout are sudden attack of burning pain, swelling in a joint, and stiffness, usually in toe. If it is not treated, over time, it can harm tendons, joints, and other tissues. NSAIDs and urate-lowering agents are preferred treatment options for gout. This analyst forecast the global gout therapeutics market to grow at a CAGR of 17.16% during the period 2016-2020. Covered in this report This report covers the present scenario and the growth prospects of the global gout therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of gout and the reve......
$2500

Global Hemophilia Drugs Market 2016-2020

Hemophilia is an X-linked genetic disorder that results in excessive blood loss during an injury, causing fatigue or even death. The disorder is more common in males and affects roughly 400,000 people globally every year. Hemophilia A is the more common form of this disorder, while hemophilia B is the rare form of hemophilia. To mitigate this disorder, plasma-derived clotting factors or recombinant clotting factors have been developed and are administered to the affected individual. The therapy is usually done in two ways: short acting therapeutic and long-acting therapeutic. The analysts forecast global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the globa......
$2500

Global Animal Antibacterial and Antibiotics Market 2016-2020

Antibacterial and antibiotic drugs are used to treat various conditions that affect animals such as companion animals, swine, cattle, horses, and fish. These drugs are also used to accelerate the growth of animals, especially in North America and Europe. However, an overuse of antibiotics has led to the development of antibiotic-resistant strains of microorganisms. This is a worrying trend as the resistant microbes could be transferred to humans through the consumption of milk or meat. The analysts forecast global animal antibacterial and antibiotics market to grow at a CAGR of 6.5% during the period 2016-2020. Covered in this report The report covers the present scenario and the growth prospects of the global animal antibacterial and antibiotics market 2016-2020. To calculate the......
$2500